Who are Juxtapid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Slentrol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lomitapide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Juxtapid — Competitive Intelligence Brief

Juxtapid (LOMITAPIDE) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Microsomal Triglyceride Transfer Protein Inhibitor. Area: Metabolic.

marketed Microsomal Triglyceride Transfer Protein Inhibitor Microsomal triglyceride transfer protein large subunit Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Juxtapid (LOMITAPIDE) — Chiesi. Juxtapid works by blocking the protein that helps transport cholesterol into the bloodstream.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Juxtapid TARGET	LOMITAPIDE	Chiesi	marketed	Microsomal Triglyceride Transfer Protein Inhibitor	Microsomal triglyceride transfer protein large subunit	2012-01-01
Slentrol	DIRLOTAPIDE		marketed		Microsomal triglyceride transfer protein large subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Microsomal Triglyceride Transfer Protein Inhibitor class)

Chiesi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Juxtapid — Competitive Intelligence Brief. https://druglandscape.com/ci/lomitapide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab